Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine and Inulin for LADA
NCT04698330Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of berberine, inulin in latent autoimmune diabetes in adults (LADA), sponsored by The Second Xiangya Hospital. Planned start May 2022; status: not yet recruiting.
02
Drugs
berberineinulin
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on NCT04698330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698330.